Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season
Top Cited Papers
Open Access
- 14 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 13 (2) , 144-147
Abstract
To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent enhancement of infection or disease severity was found for nirsevimab vs placebo recipients. Clinical Trial Registration: Clinicaltrials.gov, NCT03979313, https://clinicaltrials.gov/ct2/show/NCT03979313.Keywords
Funding Information
- AstraZeneca
- Sanofi
This publication has 12 references indexed in Scilit:
- Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infantsNature Medicine, 2023
- Nirsevimab for Prevention of RSV in Term and Late-Preterm InfantsNew England Journal of Medicine, 2023
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysisThe Lancet, 2022
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term InfantsNew England Journal of Medicine, 2022
- The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infectionsProceedings of the National Academy of Sciences, 2020
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapiesNature Microbiology, 2020
- Single-Dose Nirsevimab for Prevention of RSV in Preterm InfantsNew England Journal of Medicine, 2020
- Respiratory Syncytial Virus–Associated Hospitalizations Among Young Children: 2015–2016Pediatrics, 2020
- Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early DevelopmentClinical and Translational Science, 2018
- A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infantsScience Translational Medicine, 2017